Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6596030rdf:typepubmed:Citationlld:pubmed
pubmed-article:6596030lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6596030lifeskim:mentionsumls-concept:C1522496lld:lifeskim
pubmed-article:6596030lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:6596030lifeskim:mentionsumls-concept:C1704410lld:lifeskim
pubmed-article:6596030lifeskim:mentionsumls-concept:C1548818lld:lifeskim
pubmed-article:6596030lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:6596030pubmed:dateCreated1985-1-31lld:pubmed
pubmed-article:6596030pubmed:abstractTextCisplatinum given intravenously (i.v.), hydroxyurea given orally (os), procarbazine (os) and L-asparaginase (i.v.), on a decreasing scale, produce significant (p less than 0.01) adrenocortical activation over 4-h period at a single dose per kg 10 times higher than those employed in human therapy. Only hydroxyurea retained this activity after a 5-day treatment both in normal and Walker carcinosarcoma-bearing rats. Adrenocortical activation depends on the presence of pituitary ACTH both after single or repeated treatments.lld:pubmed
pubmed-article:6596030pubmed:languageenglld:pubmed
pubmed-article:6596030pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6596030pubmed:citationSubsetIMlld:pubmed
pubmed-article:6596030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6596030pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6596030pubmed:statusMEDLINElld:pubmed
pubmed-article:6596030pubmed:issn0171-9750lld:pubmed
pubmed-article:6596030pubmed:authorpubmed-author:PreziosiPPlld:pubmed
pubmed-article:6596030pubmed:authorpubmed-author:VaccaMMlld:pubmed
pubmed-article:6596030pubmed:issnTypePrintlld:pubmed
pubmed-article:6596030pubmed:volume7lld:pubmed
pubmed-article:6596030pubmed:ownerNLMlld:pubmed
pubmed-article:6596030pubmed:authorsCompleteYlld:pubmed
pubmed-article:6596030pubmed:pagination98-102lld:pubmed
pubmed-article:6596030pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:meshHeadingpubmed-meshheading:6596030-...lld:pubmed
pubmed-article:6596030pubmed:year1984lld:pubmed
pubmed-article:6596030pubmed:articleTitleTolerance to pituitary-adrenal axis activation by anticancer drugs in normal and tumour-bearing rats.lld:pubmed
pubmed-article:6596030pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6596030pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6596030lld:pubmed